Cite
HARVARD Citation
Chen, X. et al. (2022). A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer. 128 (11), pp. 2138-2147. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Chen, X. et al. (2022). A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer. 128 (11), pp. 2138-2147. [Online].